Treatment of bipolar disorder

Neonatal Phototherapy Market Insights, Competitive Landscape and Market Forecast Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Baby, Maternity, Health, Consumer, Medical devices, Neonatology, Clinical medicine, Medicine, Psoriasis, Medical specialties, Circadian rhythm, Light therapy, Treatment of bipolar disorder, Hepatology

What was the neonatal phototherapy market share (%) distribution in 2018 and how it will look like in 2026?

Key Points: 
  • What was the neonatal phototherapy market share (%) distribution in 2018 and how it will look like in 2026?
  • What will be the neonatal phototherapy market growth till 2026 and what will be the resultant market size in the year 2026?
  • What are the neonatal phototherapy available in the market, their product description, regulatory milestones, product development activities, research and development activities etc.?
  • What are the 7MM countries historical and forecasted market of neonatal phototherapy?

EDCare Kansas City Introduces New Adolescent Treatment Program

Retrieved on: 
Thursday, July 22, 2021
Psychiatry, Clinical medicine, Medical specialties, Psychiatric Services, Addiction psychiatry, Deinstitutionalisation, Treatment of bipolar disorder, Intensive outpatient program, Partial hospitalization, Two Rivers Psychiatric Hospital

KANSAS CITY, Mo., July 22, 2021 /PRNewswire/ -- EDCare is pleased to announce the opening of its second Adolescent Treatment Center.

Key Points: 
  • KANSAS CITY, Mo., July 22, 2021 /PRNewswire/ -- EDCare is pleased to announce the opening of its second Adolescent Treatment Center.
  • EDCare Kansas City was established in 2014 to expand EDCare's evidence-based eating disorder treatment program to the Midwest.
  • EDCare's Kansas City Adolescent Intensive Outpatient Program adds to the center's current treatment options for adults, including partial hospitalization, intensive outpatient and evening intensive outpatient treatment programs.
  • For more information about EDCare of Kansas City, or to schedule a free confidential assessment, please call 913-945-1277 or visit www.eatingdisorder.care/kansas-city-ks
    About EDCare: Since 2001, EDCare has been a leading provider of eating disorder treatment to patients across the United States and internationally.

Hendricks Behavioral Hospital to Expand Adult Outpatient Services to Meet Growing Mental Health Treatment Needs in Central Indiana

Retrieved on: 
Tuesday, July 20, 2021
Psychiatry, Psychiatric Services, Deinstitutionalisation, Drug rehabilitation, Partial hospitalization, Treatment of bipolar disorder, Intensive outpatient program, Mental health, Mental disorder, Psychiatric Institute of Washington, Desert Hope Addiction Treatment Center

However, rates of mental health and behavioral issues due to anxiety and stress from the pandemic, are on the rise.

Key Points: 
  • However, rates of mental health and behavioral issues due to anxiety and stress from the pandemic, are on the rise.
  • According to Mental Health America , the demand for behavioral health and addiction treatment services are at an unprecedented level across Indiana, with the state seeing one of the highest rates of adult prevalence of mental illness at 22.5%.
  • To meet this urgent need, Hendricks Behavioral Hospital is expanding its Partial Hospitalization Program (PHP) and Intensive Outpatient Program (IOP) for adults.
  • Hendricks Behavioral Hospital's mission is to provide outstanding care, compassionate people, and unparalleled service, offering a full continuum of inpatient and outpatient mental health and substance abuse treatment to patients in Indiana.

Groundbreaking Study Proves Columbia Protocol Predicts Those At Risk For Imminent Suicide

Retrieved on: 
Monday, July 19, 2021
Articles, Academic disciplines, Suicide prevention, Treatment of bipolar disorder, Assessment of suicide risk, Risk, Suicide, Validity, Reliability engineering, Psychology

While there are a number of effective, evidence-based interventions that can and have helped individuals at-risk, there is now a singular peer-reviewed screening tool that definitively predicts imminent death by suicide.

Key Points: 
  • While there are a number of effective, evidence-based interventions that can and have helped individuals at-risk, there is now a singular peer-reviewed screening tool that definitively predicts imminent death by suicide.
  • In a historic study recently published in Psychological Medicine, scientists in Sweden found that the Columbia Suicide Severity Risk Scale, also known as the Columbia Protocol, "robustly" predicted death by suicide over one-week, one month, and one-year periods.
  • The CDC has noted that the Columbia Protocol is "changing the paradigm in suicide risk assessment in the US and worldwide.
  • Research on the use of theColumbia Protocol has confirmed its reliability and validity for assessing risk.

Monte Nido & Affiliates to Acquire Walden Behavioral Care

Retrieved on: 
Wednesday, July 7, 2021
Mental health, Hospitals, Health, Fitness & Nutrition, Managed care, Psychiatry, Mind, Psychology, Psychiatric Services, Deinstitutionalisation, Drug rehabilitation, Partial hospitalization, Treatment of bipolar disorder, Eating disorder, Mental health

Monte Nido & Affiliates , one of the nation's most established and premier eating disorder treatment providers, today announces its intention to acquire Waltham, MA-based Walden Behavioral Care (Walden).

Key Points: 
  • Monte Nido & Affiliates , one of the nation's most established and premier eating disorder treatment providers, today announces its intention to acquire Waltham, MA-based Walden Behavioral Care (Walden).
  • View the full release here: https://www.businesswire.com/news/home/20210707005804/en/
    Walden Behavioral Care will be the fifth affiliate of Monte Nido & Affiliates, joining Monte Nido , Rosewood, Clementine Programs and Oliver-Pyatt Centers .
  • About Monte Nido & Affiliates: Monte Nido & Affiliates is one of the country's leading eating disorder treatment providers, offering a full continuum of care: inpatient, residential, partial hospitalization and intensive outpatient programs.
  • About Walden Behavioral Care: Walden Behavioral Care is a leading mental healthcare system specializing in the treatment of eating disorders.

Dr. Reddy's Laboratories Announces the Launch of Icosapent Ethyl Capsules, 1 Gram in the U.S. Market

Retrieved on: 
Tuesday, June 22, 2021
FDA, Pharmaceutical, Health, Chemistry, Physical sciences, Organic chemistry, Fish products, Biochemistry, Ethyl eicosapentaenoic acid, Polyolefins, Treatment of bipolar disorder, Ethyl group

Limitations of Use: The effect of Icosapent Ethyl Capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Key Points: 
  • Limitations of Use: The effect of Icosapent Ethyl Capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
  • Dr. Reddys Icosapent Ethyl is available in 1 gram capsules in bottle count size of 120s count.
  • Please click here to see the full prescribing information along with the approved indication for Dr. Reddys Icosapent Ethyl Capsules: https://www.drreddys.com/pi/icosapent-ethyl-1g-pi.pdf .
  • anaphylactic reaction) to Icosapent Ethyl or any of its ingredients
    What Should I Tell My Healthcare Provider Before Taking Icosapent Ethyl Capsules, 1 Gram?

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

Retrieved on: 
Thursday, May 27, 2021
Neurology, Neuropsychiatry, Treatment of bipolar disorder

Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator

Key Points: 
  • Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator
    CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced the publication of preclinical data of CY6463 in Frontiers in Pharmacology.
  • CY6463 was designed to address multiple pathophysiological features of neurodegenerative and neuropsychiatric diseases associated with cognitive impairment.
  • Extensive preclinical data from CY6463 and decades of research validate the crucial role of the sGC pathway in brain physiology and cognition.
  • Together, these data further support the clinical development of CY6463 as a novel and potentially paradigm-shifting approach to the treatment of neurodegenerative and neuropsychiatric disorders.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Diversified Pipeline to Psychedelic Revival

Retrieved on: 
Wednesday, May 19, 2021
Neurology, Neuropsychiatry, Treatment of bipolar disorder, Psilocybin, Branches of biology, Psychoactive drugs, Medical specialties

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is one of the exciting new companies to enter the public domain, bringing a diversified pipeline and de-risked strategy that should usher the company right into phase 2 clinical trials.

Key Points: 
  • Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is one of the exciting new companies to enter the public domain, bringing a diversified pipeline and de-risked strategy that should usher the company right into phase 2 clinical trials.
  • Tryp\xe2\x80\x99s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (\xe2\x80\x9cPFN\xe2\x80\x9d), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders.
  • In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma.
  • Mobile Phones Only)\nPlease see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer\n'

Evolve Treatment Centers Opens Outpatient Facility in Danville, California

Retrieved on: 
Monday, May 3, 2021
Psychiatry, Medical specialties, Clinical medicine, Psychiatric Services, Drug rehabilitation, Deinstitutionalisation, Partial hospitalization, Treatment of bipolar disorder, Cognitive behavioral therapy, Mental health

b'DANVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Evolve Treatment Centers is pleased to announce the expansion of its mental health programs in Northern California with the opening of a new Partial Hospitalization Program (PHP) and Intensive Outpatient (IOP) treatment center.

Key Points: 
  • b'DANVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Evolve Treatment Centers is pleased to announce the expansion of its mental health programs in Northern California with the opening of a new Partial Hospitalization Program (PHP) and Intensive Outpatient (IOP) treatment center.
  • Evolve Danville Outpatient will serve teens struggling with mental health, addiction, and behavioral issues.\n\xe2\x80\x9cWe take great pride in the fact that our new outpatient center, together with Evolve Danville Residential Treatment Center, now offers a full continuum of care for adolescents in the area,\xe2\x80\x9d says Ellen Bloch, LCSW, Director of Outpatient Programs at Evolve.
  • "Our new facility provides clients who receive care at any of our residential treatment centers throughout California the opportunity to continue within Evolve\'s excellent infrastructure of treatment.
  • "\nAt\xc2\xa0Evolve Danville Outpatient, licensed, trained staff provide evidence-based treatment, including Dialectical Behavior Therapy (DBT) , Cognitive Behavioral Therapy (CBT) ,\xc2\xa0and more.

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

Retrieved on: 
Monday, May 3, 2021
Psychiatric diagnosis, Mood disorders, Psychiatry, Abnormal psychology, Depression, Bipolar spectrum, Emotion, Bipolar disorder, Treatment of bipolar disorder, Bipolar I disorder, Bipolar II disorder, Psychosis

Bipolar I and Bipolar II each represent about half of the overall population of patients with bipolar disorder.\nBipolar depression is the most common clinical presentation of bipolar disorder.

Key Points: 
  • Bipolar I and Bipolar II each represent about half of the overall population of patients with bipolar disorder.\nBipolar depression is the most common clinical presentation of bipolar disorder.
  • Bipolar depression remains a significantly underserved medical need, with only a few\xc2\xa0FDA-approved treatment options available.
  • These treatments are commonly associated with tolerability issues.\nCAPLYTA\xc2\xae (lumateperone) is under investigation for the treatment of bipolar disorder.
  • CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.\nContraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA.